Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After CEO’s Abrupt Resignation, Teva Management Emphasizes Stability

Executive Summary

A day after announcing the abrupt resignation of CEO Jeremy Levin, Teva’s management emphasized that the company’s current strategy would continue, including plans for dealing with ongoing pressures from Copaxone’s loss of exclusivity, and under-performance of the European generics businesses. Teva hoped to persuade rattled investors of its steady road to growth.

Advertisement

Related Content

Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?
J.P. Morgan Notebook: Wednesday, January 15
People In The News: Former Federal Officials On The Move; Changes At Aurinia, Neo, Mallinckrodt, Lilly, And More
Deals Of The Week Searches For Meaning In Deal Break-Ups
A More Disciplined Teva Gets Lukewarm Reception From Street
Mesoblast Advances Stem-Cell Drugs As Catalysts Approach
Fourth Time’s The Charm? Teva Cites Colloids in Latest Attempt to Convince FDA to Require Clinical Trials for Generic Copaxone
Teva Swoops In To Snatch Cephalon For $6.7 Billion

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055714

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel